🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Senseonics Holdings, Inc. SENS PHARMA

Healthcare · Medical Devices · United States
https://www.senseonics.com
Company Profile ↓
$9.33
-3.22% 1Y
Mkt Cap$493.31M
P/E-4.17
P/B5.61
52W High$11.30
52W Low$4.86
Book Value$1.71
EPS (TTM)$-2.24

Company Overview

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 113.7% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $35.26M (+56.9% YoY); net profit $-69.11M.
  • Trailing 12 Months Year-on-year growth — revenue +117.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 113.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:113.66%
1 Year:117.80%

Stock Price Performance

1 Year:-3.22%
6 Months:+47.86%
3 Months:+30.86%
1 Month:+32.91%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 69% of range
$4.86 $11.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross3d ago
  • RSI (14)63.69 · Neutral
Price Performance
1M+32.91%
3M+30.86%
6M+47.86%
1Y-3.22%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 113.7% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.17
Industry PE
24.83
Forward P/E
-4.79
PEG Ratio
-
Book Value
$1.71
Price to Book
5.61
P/S
10.43
EV/EBITDA
-4.01
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
113.66%
Profit 5Y
-
Revenue (YoY)
117.80%
Earnings (YoY)
-

Profitability & Returns

ROCE
-67.05%
ROE
-118.24%
ROA
-41.41%
Profit Margin
-
Op Margin
-
Gross Margin
54.87%
EPS (Latest Qtr)
$-0.71
EPS (TTM)
$-2.24

Balance Sheet & Liquidity

Debt/Equity
0.70
Quick Ratio
6.22
Current Ratio
6.75
Debt
$62.82M
Total Assets
$102.86M
Current Assets
$92.28M
Working Capital
$93.19M

Ownership

Promoter Holding
9.86%
Chg in Prom Hold
0.03%
FII / Inst Holding
39.63%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$493.31M
Total Revenue (TTM)
$48.55M
EBITDA
$-106.51M
Free Cash Flow
$-59.24M
Operating Cash Flow
$-95.94M
Shares Outstanding
52.87M
Gross Margin
54.87%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SENS Senseonics Holdings, Inc. PHARMA 9.33 -4.17 $493.31M 0.00% -67.05% -118.24% 113.66% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------553.00K814.00K2.10M2.91M2.95M553.00K837.00K7.19M1.24M1.48M959.00K-31.00K216.00K514.00K-487.00K433.00K276.00K292.00K137.00K4.62M4.14M4.13M6.10M5.05M4.87M4.26M-6.26M6.65M8.10M14.26M11.71M
Cost of Revenue -----------------------------------4.75M3.53M4.63M6.59M4.77M
Gross Profit ----15.00K-77.00K-236.00K-492.00K-900.00K-860.00K-1.13M-362.00K-216.00K-2.58M-4.98M-3.31M-4.55M-3.34M-8.24M-19.63M-1.14M835.00K2.58M526.00K392.00K-1.25M527.00K824.00K756.00K414.00K417.00K1.17M335.00K298.00K-4.05M-1.50M3.12M3.47M7.67M6.94M
Operating Expenses -----------------------------------14.99M17.44M23.07M28.59M38.79M
Operating Income -8.31M-8.19M-10.93M-11.55M-10.51M-9.44M-12.40M-11.64M-16.61M-15.67M-15.93M-20.06M-22.98M-28.61M-29.77M-34.65M-31.36M-34.88M-43.83M-12.53M-12.47M-10.31M-11.32M-15.89M-16.03M-15.16M-17.04M-17.57M-19.71M-19.87M-19.02M-18.23M-19.49M-22.85M--13.49M-14.32M-19.60M-20.93M-31.85M
EBITDA ------------------------------------12.45M-12.99M-17.98M-19.23M-30.60M
Interest Expense -----------------------------------1.43M1.15M1.17M1.21M1.19M
Pretax Income ------------------------------------14.26M-14.50M-19.53M-20.82M-32.33M
Tax Provision ----------------------------------------
Net Income -8.59M-8.41M-11.22M-11.86M-10.89M-9.96M-13.07M-12.37M-17.38M-16.27M-22.27M-32.50M-31.88M-7.32M-29.36M-31.07M-19.50M-35.61M-42.59M-7.51M-23.43M-101.63M-249.51M-180.31M42.91M86.72M104.23M-60.39M1.32M-20.42M-24.10M-18.88M-20.29M-23.98M--14.26M-14.50M-19.53M-20.82M-32.33M
Diluted EPS ---------------------0.10--0.68-0.420.08-0.03-0.03-0.130.00-0.04-0.04-0.03-0.03-0.77--0.02-0.02-0.43--0.71
R&D Expense 4.68M-6.42M7.54M6.88M-7.00M5.60M9.77M-8.11M8.29M7.40M-7.11M10.50M11.08M-7.36M3.80M4.57M-5.25M7.11M7.20M7.80M9.30M10.98M12.40M12.83M12.77M10.44M10.80M10.55M-7.30M7.71M7.76M-8.61M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2014Jun 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --38.00K332.00K529.00K2.04M4.92M1.37M-16.39M22.39M22.47M35.26M
Cost of Revenue ---------13.66M19.30M21.94M19.49M
Gross Profit --38.00K-328.00K-3.38M-8.15M-19.45M-17.37M-2.73M3.09M533.00K15.76M
Operating Expenses ---------71.35M78.69M75.38M84.10M
Operating Income -18.70M--28.81M-42.43M-56.31M-87.58M-130.66M-79.13M--68.63M-75.60M-74.84M-68.34M
EBITDA ---------161.81M-48.01M-68.70M-62.65M
Interest Expense ---------18.70M11.11M8.44M4.95M
Pretax Income ---------142.12M-60.39M-78.62M-69.11M
Tax Provision -------------
Net Income -18.89M-67.59K-29.88M-43.93M-59.10M-93.97M-115.55M-175.17M-142.12M-60.39M-78.62M-69.11M
Diluted EPS -------0.61-0.77--0.11-0.11-2.50-1.66
R&D Expense 12.88M-18.25M26.35M30.73M31.86M38.43M20.41M27.22M39.72M48.75M41.14M31.59M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2013Jun 2014Dec 2014Jun 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -10.00K20.00M9965.42M22.27M45.94M159.97M132.80M35.92M-177.67M138.22M100.44M126.27M
Current Assets -----------161.20M130.03M91.44M117.53M
Cash & Equivalents 8.25M-18.92M-3.94M13.05M16.15M136.79M95.94M18.00M-35.79M75.71M74.60M40.23M
Inventory -----------7.31M8.78M4.42M6.70M
Receivables -----------2.45M4.53M6.29M12.12M
Total Liabilities --12.08M-15.12M27.15M38.68M88.71M141.45M177.19M-180.25M102.42M116.99M65.22M
Current Liabilities -2.92K2.04M46.51K7.33M11.62M23.14M28.89M126.71M16.64M-31.47M17.26M38.85M24.35M
Long Term Debt --------11.80M57.22M-56.38M41.20M34.70M35.59M
Total Debt -----------75.38M47.78M61.05M41.37M
Total Equity 6.16M7.08K7.91M-45.51K-9.70M-4.88M7.27M71.26M-8.65M-144.08M--2.58M35.80M-16.55M61.05M
Shares Outstanding -----------479.64M530.36M595.35M41.27M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -10.27K-25.46M-38.02M-55.74M-90.77M-136.05M-67.42M--66.31M-70.16M-60.47M-59.13M
Investing Cash Flow --202.00K-7.77M-13.23M19.43M-1.04M-181.00K-26.88M89.71M32.84M-53.42M
Financing Cash Flow 4.73K10.68M54.89M72.07M191.99M96.24M-10.13M-41.76M20.37M26.83M78.19M
Capital Expenditure ---------312.00K-350.00K-2.24M-1.12M
Free Cash Flow ---------66.62M-70.51M-62.70M-60.24M
Net Change in Cash --------2.33M39.92M-797.00K-34.36M

Ratios (Annual)

Figures in %.

Metric Dec 2014Jun 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --100.0%-98.8%-639.9%-399.5%-395.0%-1,269.4%-16.6%13.8%2.4%44.7%
Operating Margin % ---75,821.1%-12,781.0%-10,645.2%-4,295.1%-2,653.6%-5,784.4%--418.7%-337.7%-333.0%-193.8%
Net Margin % ---78,623.7%-13,231.9%-11,172.2%-4,608.7%-2,346.6%-12,804.7%-867.2%-269.7%-349.8%-196.0%
ROE % -238.7%148.5%308.1%900.8%-813.3%-131.9%1,336.0%121.6%--5,517.0%-168.7%474.9%-113.2%
ROCE % -104.2%-1,506.9%-398.6%-246.9%-66.8%-2,144.5%-410.4%--46.9%-62.5%-121.5%-67.0%

Shareholding Pattern

Insiders
9.86%
Institutions
39.63%
Public Float
43.96%

Top Institutional Holders

#Holder% HeldSharesValue
1 Sessa Capital IM, L.P. 10.62% 4.44M $42.51M
2 Blackrock Inc. 6.68% 2.79M $26.76M
3 Vanguard Capital Management LLC 4.26% 1.78M $17.05M
4 Avidity Partners Management, LP 3.83% 1.60M $15.33M
5 Sio Capital Management, LLC 3.81% 1.59M $15.26M
6 UBS Group AG 3.56% 1.49M $14.25M
7 Geode Capital Management, LLC 2.71% 1.13M $10.85M
8 Masters Capital Management, LLC 1.67% 700.00K $6.71M
9 State Street Corporation 1.22% 511.12K $4.90M
10 Marshall Wace LLP 0.97% 405.69K $3.89M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SENS

Yahoo Finance Fri, 07 Aug 2026

Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date. Net revenue fo…

Yahoo Finance hu, 06 Aug 2026

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-yearRaising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of …

Yahoo Finance ue, 14 Jul 2026

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 16.8 Billion in 2…

Yahoo Finance Wed, 01 Jul 2026

Senseonics Holdings (SENS) Stock Fair Value Moves Lower After Analysts Cut Growth Assumptions

Analysts have reset their average price target for Senseonics Holdings to about US$13.80, down from around US$18.92, reflecting a roughly 27% cut in the equity value embedded in their models. Recent commentary focuses on how this new target…

Yahoo Finance Mon, 29 Jun 2026

Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?

Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo Finance Mon, 01 Jun 2026

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitorin…

SENS — Frequently Asked Questions

What is the current share price of Senseonics Holdings, Inc. (SENS)?

As of 2026-09-19 21:16 PDT, Senseonics Holdings, Inc. (SENS) trades at $9.33 on NasdaqGS. Its 52-week range is $4.86 to $11.30.

What is the market capitalisation of SENS?

Senseonics Holdings, Inc. (SENS) has a market capitalisation of $493.31M on NasdaqGS.

What is the P/E ratio of SENS?

SENS trades at a trailing price-to-earnings (P/E) ratio of -4.17. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.61.

What is the return on equity (ROE) of SENS?

SENS has a return on equity (ROE) of -118.24%. Its return on capital employed (ROCE) is -67.05%.

Is SENS a good stock to buy?

This page provides a data-driven analysis of Senseonics Holdings, Inc. (SENS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space